: Tempest Therapeutics’ stock jumps 1,900% as liver-cancer treatment shows promise

The drug candidate showed clinical superiority as a first-line treatment for unresectable or metastatic hepatocellular carcinoma, a common type of liver cancer.

Previous post : German sandal maker Birkenstock’s stock set to open below its IPO issue price
Next post Key Words: Pioneer’s CEO cheers Exxon’s ‘great dividend.’ Here’s how much he could make.